Recent clinical trials have produced many encouraging data for CAR-T cell therapy against various types of cancers, which inspires further development of CAR-T cell therapies. Preclinical in vivo therapeutic efficacy test of CAR-T cells in animal models provides valuable information for their later clinical application. With years of preclinical in vivo research and project management experience, Creative Biolabs is able to provide therapeutic efficacy test service for a proof-of-concept or therapeutic efficacy validation, by utilizing appropriate animal models, designing comprehensive research practices and handling high-quality in vivo studies.
We are able to conduct many tests to evaluate the therapeutic efficacy of the CAR-T cell therapy. The techniques used in our platform includes but not limited to the following categories.
In Vivo Imaging
In vivo imaging techniques, including bioluminescence imaging (BLI) and positron emission tomography (PET), allow for non-invasive study of ongoing tumor progression in animal models with or without the administration of CAR-T cells throughout the whole evaluation duration.
With flow cytometry, cells from peripheral blood or harvested tissues such as bone marrow, liver and spleen are qualitatively and quantitatively determined by detecting specific targets and markers.
Histologic and Pathologic Analysis
The results of the presence and infiltration of tumor cells can be confirmed by histologic analysis of animal tissue sections such as bone marrow, spleen, the periodontal region and calvarium. Immunohistochemistry allows for morphometric and visualization analysis of tumor cells and CAR-T cells with highly specific antibodies labeled with visible markers.
Characteristics, including feed consumption, body weight, behavior and morphology are closely monitored. After specific end point, a complete necropsy including the assessment of organ weight and histopathology analysis is conducted. The survival data are also recorded and statistically analyzed properly.
All of our studies are performed in a GLP-compliant and IACUC-regulated facility by experienced technicians. We are dedicated to providing the best-characterized therapeutic efficacy test services for CAR-T cell therapy development to help our customers and expedite their IND application. For rmore details, please click in vivo generation of CAR T cells in human CD4+ lymphocytes.
All services and products are only for lab research use, not for any clinical diagnosis or treatment.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE